Click here for more biotechnology stock analysis and recommendations from John McCamant in Medical Technology Stock Letter.

FORBES: Biotech Pipeline Play

John McCamant, editor of the Medical Technology Stock Letter, urges his readers not to bail on biotech.

FORBES: Magazine Article

Overvaluation is also a theme with John McCamant, co-editor of the Medical Technology Stock Letter in Berkeley, Calif.

FORBES: Beware Of Biotechs At Cancer-Cure Prices

"Later this week, investors will be focused on some key economic data, including retail sales data and wholesale prices, " points out John McCamant in a hotline for the Medical Technology Stock Letter.

FORBES: Hotlines From Dow 11,000

Jim McCament, editor of the Medical Technology Stock Letter, speculated in an update yesterday that some investors were simply selling on the news, a trend he said he sees often with small biotech stocks.

FORBES: Magazine Article

Matt Berry, associate analyst at John McCamant's Medical Technology Stock Letter, says much of the malaise in the current market is fallout from the ImClone (nasdaq: IMCL - news - people ) fiasco.

FORBES: Will Biotech Boom Again?